Stock comparison
Genmab A/S
Koninklijke Philips N.V.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
PHG
Koninklijke Philips N.V.
Market cap
$25.66B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | PHG | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 38D | GMAB |
| Benjamin Graham | 64C | 36D | GMAB |
| Philip Fisher | 48D | 38D | GMAB |
| Peter Lynch | 25F | 44D | PHG |
| Joel Greenblatt | 76B | 30F | GMAB |
| Charlie Munger | 68C | 36D | GMAB |
| Terry Smith | 71C | 33F | GMAB |
Side-by-side metrics
| Metric | GMAB | PHG |
|---|---|---|
| Market cap | $16.5B | $25.66B |
| P/E (TTM) | 6.2x | 21.4x |
| EV/EBIT | 12.0x | 18.5x |
| ROIC (TTM) | 43.78% | 5.76% |
| Gross margin | 93.88% | 45.2% |
| Net margin | 18.23% | 5.5% |
| Revenue CAGR 5y | -18.45% | 0.97% |
| EPS CAGR 5y | -23.48% | 9.12% |
| Debt / Equity | 0.1x | 0.7x |
| Dividend yield | 0.0% | 3.89% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 0.7x+90%
- ROIC (TTM)43.78%vs 5.76%+87%
- P/E (TTM)6.2xvs 21.4x+71%
- Net margin18.23%vs 5.5%+70%
PHG leads on
- EPS CAGR 5y9.12%vs -23.48%+139%
- Revenue CAGR 5y0.97%vs -18.45%+105%
- Dividend yield3.89%vs 0.0%+100%
- Market cap$25.66Bvs $16.5B+36%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.